CapsoVision Inc
CV13.810USD
+0.910+7.05%
Market hours （ET）Quotes delayed by 15 min
646.29MMarket Cap
LossP/E TTM
More Details of CapsoVision Inc Company
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
CapsoVision Inc Info
Ticker SymbolCV
Company nameCapsoVision Inc
IPO dateJul 02, 2025
CEOWang (Kang-Huai)
Number of employees90
Security typeOrdinary Share
Fiscal year-endJul 02
Address18805 Cox Avenue
CitySARATOGA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code95070
Phone14086241488
Websitehttps://www.capsovision.com/
Ticker SymbolCV
IPO dateJul 02, 2025
CEOWang (Kang-Huai)
Company Executives of CapsoVision Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kang-Huai (Johnny) Wang
Mr. Kang-Huai (Johnny) Wang
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.10M
--
Mr. Chen Lung Tsai
Mr. Chen Lung Tsai
Independent Chairman of the Board
Independent Chairman of the Board
115.46K
--
Mr. Wen-Herng Henry King
Mr. Wen-Herng Henry King
Independent Director Nominee
Independent Director Nominee
41.42K
--
Ms. Hui Ying (Patty) Kuo
Ms. Hui Ying (Patty) Kuo
Independent Director
Independent Director
20.71K
--
Mr. Douglas Atkinson
Mr. Douglas Atkinson
Head - Global Sales
Head - Global Sales
--
--
Ms. Heidi Chung Sutardja
Ms. Heidi Chung Sutardja
Director
Director
--
--
Mr. David Garcia
Mr. David Garcia
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Ms. Keri Jorgenson
Ms. Keri Jorgenson
Director of Clinical Operations
Director of Clinical Operations
--
--
Mr. Howard Lee
Mr. Howard Lee
Director
Director
--
--
Mr. Pen-Jung Tseng
Mr. Pen-Jung Tseng
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kang-Huai (Johnny) Wang
Mr. Kang-Huai (Johnny) Wang
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.10M
--
Mr. Chen Lung Tsai
Mr. Chen Lung Tsai
Independent Chairman of the Board
Independent Chairman of the Board
115.46K
--
Mr. Wen-Herng Henry King
Mr. Wen-Herng Henry King
Independent Director Nominee
Independent Director Nominee
41.42K
--
Ms. Hui Ying (Patty) Kuo
Ms. Hui Ying (Patty) Kuo
Independent Director
Independent Director
20.71K
--
Mr. Douglas Atkinson
Mr. Douglas Atkinson
Head - Global Sales
Head - Global Sales
--
--
Ms. Heidi Chung Sutardja
Ms. Heidi Chung Sutardja
Director
Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
FY2023
By BusinessUSD
Name
Revenue
Proportion
Products (capsules and capsule reading devices)
3.12M
93.97%
Services (cloud-based video delivery and reading services)
200.00K
6.03%
By RegionUSD
Name
Revenue
Proportion
United States
2.55M
77.01%
Outside United States
762.00K
22.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Products (capsules and capsule reading devices)
3.12M
93.97%
Services (cloud-based video delivery and reading services)
200.00K
6.03%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Harari Eliyahou Et Al
9.19%
Ching-Hang (Shen)
8.52%
Kioxia Corporation
7.36%
CID Greater China Venture Capital Fund III, L.P.
6.67%
Shih-Chang (Stephen Wu)
5.04%
Other
63.22%
Shareholders
Shareholders
Proportion
Harari Eliyahou Et Al
9.19%
Ching-Hang (Shen)
8.52%
Kioxia Corporation
7.36%
CID Greater China Venture Capital Fund III, L.P.
6.67%
Shih-Chang (Stephen Wu)
5.04%
Other
63.22%
Shareholder Types
Shareholders
Proportion
Individual Investor
17.40%
Corporation
14.03%
Other Insider Investor
9.19%
Investment Advisor/Hedge Fund
0.42%
Investment Advisor
0.35%
Hedge Fund
0.06%
Research Firm
0.02%
Pension Fund
0.02%
Bank and Trust
0.01%
Other
58.50%
Institutional Shareholding
Updated: Fri, Sep 12
Updated: Fri, Sep 12
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
11
196.14K
0.42%
+171.24K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Harari Eliyahou Et Al
4.31M
9.21%
+4.31M
--
Jul 02, 2025
Ching-Hang (Shen)
3.91M
8.36%
+3.91M
--
Jul 02, 2025
Kioxia Corporation
3.45M
7.37%
+3.45M
--
Jul 02, 2025
CID Greater China Venture Capital Fund III, L.P.
3.13M
6.68%
+3.13M
--
Jul 02, 2025
Shih-Chang (Stephen Wu)
2.36M
5.05%
+2.36M
--
Jul 02, 2025
Wang (Kang-Huai)
1.10M
2.36%
+1.10M
--
Jul 03, 2025
Harari (Michele)
573.91K
1.23%
+573.91K
--
Jul 02, 2025
Tsai (Chen Lung)
115.46K
0.25%
+115.46K
--
Jul 02, 2025
Geode Capital Management, L.L.C.
24.90K
0.05%
--
--
Aug 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CapsoVision Inc?
The top five shareholders of CapsoVision Inc are:
Harari Eliyahou Et Al holds 4.31M shares, accounting for 9.21% of the total shares.
Ching-Hang (Shen) holds 3.91M shares, accounting for 8.36% of the total shares.
Kioxia Corporation holds 3.45M shares, accounting for 7.37% of the total shares.
CID Greater China Venture Capital Fund III, L.P. holds 3.13M shares, accounting for 6.68% of the total shares.
Shih-Chang (Stephen Wu) holds 2.36M shares, accounting for 5.05% of the total shares.
Harari Eliyahou Et Al holds 4.31M shares, accounting for 9.21% of the total shares.
Ching-Hang (Shen) holds 3.91M shares, accounting for 8.36% of the total shares.
Kioxia Corporation holds 3.45M shares, accounting for 7.37% of the total shares.
CID Greater China Venture Capital Fund III, L.P. holds 3.13M shares, accounting for 6.68% of the total shares.
Shih-Chang (Stephen Wu) holds 2.36M shares, accounting for 5.05% of the total shares.
What are the top three shareholder types of CapsoVision Inc?
The top three shareholder types of CapsoVision Inc are:
Harari Eliyahou Et Al
Ching-Hang (Shen)
Kioxia Corporation
Harari Eliyahou Et Al
Ching-Hang (Shen)
Kioxia Corporation
How many institutions hold shares of CapsoVision Inc (CV)?
As of 2025Q3, 11 institutions hold shares of CapsoVision Inc, with a combined market value of approximately 196.14K, accounting for 0.42% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for CapsoVision Inc?
In FY2025Q2, the Products (capsules and capsule reading devices) business generated the highest revenue for CapsoVision Inc, amounting to 3.12M and accounting for 93.97% of total revenue.
